IL315405A - Methods for treating recurrent epithelioid sarcoma using bispecific anti-MUC16 and anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies - Google Patents

Methods for treating recurrent epithelioid sarcoma using bispecific anti-MUC16 and anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies

Info

Publication number
IL315405A
IL315405A IL315405A IL31540524A IL315405A IL 315405 A IL315405 A IL 315405A IL 315405 A IL315405 A IL 315405A IL 31540524 A IL31540524 A IL 31540524A IL 315405 A IL315405 A IL 315405A
Authority
IL
Israel
Prior art keywords
antibodies
muc16
methods
combination
bispecific
Prior art date
Application number
IL315405A
Other languages
English (en)
Hebrew (he)
Inventor
Barcellos Goncalves Priscila Hermont
Original Assignee
Regeneron Pharma
Barcellos Goncalves Priscila Hermont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Barcellos Goncalves Priscila Hermont filed Critical Regeneron Pharma
Publication of IL315405A publication Critical patent/IL315405A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL315405A 2022-03-17 2023-03-16 Methods for treating recurrent epithelioid sarcoma using bispecific anti-MUC16 and anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies IL315405A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263320961P 2022-03-17 2022-03-17
US202263350503P 2022-06-09 2022-06-09
PCT/US2023/015347 WO2023177772A1 (en) 2022-03-17 2023-03-16 Methods of treating recurrent epithelioid sarcoma with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies

Publications (1)

Publication Number Publication Date
IL315405A true IL315405A (en) 2024-11-01

Family

ID=86054295

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315405A IL315405A (en) 2022-03-17 2023-03-16 Methods for treating recurrent epithelioid sarcoma using bispecific anti-MUC16 and anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies

Country Status (9)

Country Link
EP (1) EP4493280A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025509567A (cg-RX-API-DMAC7.html)
KR (1) KR20240159849A (cg-RX-API-DMAC7.html)
CN (1) CN119677534A (cg-RX-API-DMAC7.html)
AU (1) AU2023236126A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245946A1 (cg-RX-API-DMAC7.html)
IL (1) IL315405A (cg-RX-API-DMAC7.html)
MX (1) MX2024011298A (cg-RX-API-DMAC7.html)
WO (1) WO2023177772A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202617776A (zh) * 2024-07-10 2026-05-01 美商再生元醫藥公司 治療smarcb1缺陷型癌症之方法
CN119632993B (zh) * 2024-12-04 2025-09-23 安徽医科大学 他泽司他在制备治疗急性肾损伤的药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
KR102531251B1 (ko) 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
JP7743314B2 (ja) * 2019-06-21 2025-09-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Muc16およびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用

Also Published As

Publication number Publication date
WO2023177772A1 (en) 2023-09-21
EP4493280A1 (en) 2025-01-22
KR20240159849A (ko) 2024-11-06
CA3245946A1 (en) 2023-09-21
AU2023236126A1 (en) 2024-09-19
CN119677534A (zh) 2025-03-21
JP2025509567A (ja) 2025-04-11
MX2024011298A (es) 2024-12-06

Similar Documents

Publication Publication Date Title
IL279251A (en) Methods for treating cancer with bispecific antibodies against CD3XMUC16 and antibodies against PD-1
IL290255A (en) Anti-ctla4/anti-pd-1 bispecific antibody and use thereof
PH12020550408A1 (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
HUE070224T2 (hu) Bispecifikus anti-BCMA X anti-CD3 antitestek és azok alkalmazásai
JOP20200213A1 (ar) جزيئات رابطة لـ pd-1 وطرق استخدامها
EA201891495A1 (ru) Биспецифические анти-cd20/анти-cd3 антитела для лечения острого лимфобластного лейкоза
IL313864A (en) Methods for treating recurrent ovarian cancer using bispecific antibodies against MUC16 and against CD3 alone or in combination with antibodies against PD-1
IL307821A (en) Dosage for treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody
IL319877A (en) Methods for treating cancer with bispecific EGFR X CD28 antibodies alone or in combination with anti-PD-1 antibodies
EP4467571A4 (en) Bispecific Antibody: Anti-CD3 and Anti-CD20 and its Use
EP4483877A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING A BISPECIFIC ANTI-CTLA4-ANTI-PD-1 ANTIBODY AND CHIAURANIB
IL288916B2 (en) Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation
SI4157876T1 (sl) Anti-PD-1 protitelesa
MX2024011298A (es) Métodos para tratar el sarcoma epitelioide recurrente con anticuerpos biespecíficos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1
HK40122871A (en) Methods of treating recurrent epithelioid sarcoma with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
CA3261147A1 (en) DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
HK40118892A (en) Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
IL312813A (en) Methods for treating cancer using bispecific antibodies against CD3 and MUC16 and antibodies against CTLA-4
IL315768A (en) Bispecific anti-CD3 and anti-PD-L1 activatable proteins and their uses
IL316751A (en) Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and anti-CD3 alone or in combination with anti-PD-1 antibodies
IL315307A (en) Treatment methods using CTLA-4 and PD-1 bispecific antibodies
SG11202105078XA (en) Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer
IL318036A (en) Bispecific anti-PCRV and PSL antibodies for the treatment of bronchiectasis
CA3269085A1 (en) Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies
HK40130891A (en) Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies